Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study of Vorinostat (Suberoylanilide Hydroxamic Acid) Plus Rituximab in Indolent Non-Hodgkin's Lymphoma

NCT00720876 is registered in ClinicalTrials.gov with City of Hope Medical Center as lead sponsor.

NCT NCT00720876
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00720876 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study of Vorinostat (Suberoylanilide Hydroxamic Acid) Plus Rituximab in Indolent Non-Hodgkin's Lymphoma
Lead sponsor
City of Hope Medical Center
Phase
Phase 2
Overall status
Completed
Start date
July 23, 2008
Completion date
June 8, 2017
Enrollment
30 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

lymphoma